August 5, 2014 - The court approved the settlement, entered the orders approving the plan of allocation, the motion for attorneys’ fees and expenses, and dismissed the action with prejudice.
April 1, 2014 - The court preliminarily approved the settlement.

March 27, 2014 - Parties filed a stipulation of settlement.

April 15, 2013 - The lead plaintiffs filed a third amended complaint.

March 15, 2013 - The lead plaintiffs filed a second amended complaint.

February 13, 2013 - The court granted in part and denied in part the defendants' motion to dismiss without prejudice.

August 27, 2012 - The defendants filed a motion to dismiss.

June 25, 2012 - The lead plaintiffs filed an amended consolidated complaint on behalf of investors who purchased Hospira Inc (NYSE: HSP) common shares between February 4, 2010 and October 17, 2011. The lead plaintiffs allege that the defendants violated the Securities Exchange Act of 1934 by issuing false and misleading statements between February 4, 2010 and October 17, 2011.

April 18, 2012 - The lead plaintiffs and lead counsel were appointed and all cases were consolidated.

January 20, 2012 - Lead plaintiff motions were filed.

November 21, 2011 - An investor in shares of Hospira Inc (NYSE: HSP) filed a lawsuit in U.S. District Court for the Northern District of Illinois against Hospira Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between March 24, 2009 and October 17, 2011.

According to the complaint the plaintiff alleges on on behalf of purchasers of the Hospira Inc (NYSE: HSP) common stock between March 24, 2009, and October 17, 2011, that Hospira Inc and certain of its officers and executives violated the Securities Exchange Act of 1934 by issuing materially false and misleading statements regarding Hospira Inc's business and financial results.

While Hospira Inc’s annual Revenue rose from $3.87 billion in 2009 to $3.91 billion in 2010, its Net Income fell from $403.90 million in 09 to $357.20 million in 2010. Its second quarter Revenue rose from $949.30 million last year to $976.70 million this year, but its Net Income fell from a second quarter 2010 Net Income of $71.40 million to a second quarter 2011 Net Loss of $88.90 million.

Shares of Hospira Inc (NYSE: HSP) rose from as low as $22.21 in March 2009 to as high as almost $60 per share during 2010.

During the first half of 2011 Hospira Inc (NYSE: HSP) shares traded above $50 per share and reached in June over $58 per share.

Then on October 18, 2011, Hospira Inc (NYSE: HSP) announced certain preliminary third-quarter 2011 results and lowered its FY 2011 EPS Guidance. Among other things, Hospira Inc also said that its adjusted income from operations and adjusted earnings per share are lower than anticipated primarily due to certain quality actions taken in response to a U.S. Food and Drug Administration (“FDA”) 2010 warning letter and subsequent observations related to Hospira Inc's manufacturing facility in Rocky Mount, North Carolina, and device quality and supply-related issues.

Shares of Hospira Inc (NYSE: HSP) dropped from $37.49 on October 17 to $29.51 on October 18, 2011. In fact, since June 2011 Hospira Inc (NYSE: HSP) shares fell from almost $55 per share to as low as $28.67 per share on October 20, 2011.